A phase II study of brentuximab vedotin in patients with relapsed or refractory Epstein-Barr virus-positive and CD30-positive lymphomas.

Like Comment
Not available.

View the full article @ Haematologica

Get PDF with LibKey
Authors: Miso Kim, Jeong-Ok Lee, Jiwon Koh, Tae Min Kim, Ji Yun Lee, Yoon Kyung Jeon, Bhumsuk Keam, Dong-Wan Kim, Jong Seok Lee, Dae Seog Heo


The wider, wiser view for healthcare professionals. ClinOwl signposts the latest clinical content from over 100 leading medical journals.
6584 Contributions
0 Following